A 2-PART SEAMLESS PART A (PHASE 2)/PART B (PHASE 3) RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF BIIB059 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS WITH OR WITHOUT SYSTEMIC MANIFESTATIONS AND REFRACTORY AND/OR INTOLERANT TO ANTIMALARIAL THERAPY (AMETHYST

Registry ID

230LE301

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE3

Study type

INTERVENTIONAL

Sponsor

BIOGEN CANADA INC

Start date

2023-02-24

Last update

2022-09-14

Conditions

• SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS

Related clinical trials

• A PHASE 2B, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY TO ASSESS THE SAFETY, TOLERABILITY, AND EFFICACY OF IMVT-1402 IN PARTICIPANTS WITH ACTIVE SUBACUTE CUTANEOUS LUPUS ERYTHEMATOSUS (SCLE) AND/OR CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS (CCLE) WITH OR WITHOUT SYSTEMIC MANIFESTATIONS
• A RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, PROOF OF CONCEPT STUDY ASSESSING THE EFFICACY AND SAFETY OF THE RIPK1-INHIBITOR SAR443122 IN PATIENTS WITH MODERATE TO SEVERE SUBACUTE OR DISCOID/CHRONIC CUTANEOUS LUPUS ERYTHEMATOSUS

View on source registry